Company* (Country; Symbol) | Product |
Description | Indication |
Status (Date) |
AUTOIMMUNE | ||||
Amgen Inc. (AMGN) and Genmab A/S (Denmark; CSE:GEN) |
HuMax-IL15/ AMG 714 |
Human antibody against interleukin-15 |
Rheumatoid arthritis |
Interim analysis on 115 patients in Phase II trial showed a significant difference between drug patients and those on placebo (3/22) |
Astralis Ltd. (OTC BB: ASTR) |
Psoraxine |
Protein-based immuno-stimulator |
Psoriasis |
Company began 120-patient Phase II trial to evaluate safety and efficacy of repeated administrations in patients with moderate to severe plaque (3/29) |
Celltech Group plc (UK; NYSE: CLL) |
CDP870 |
Product that uses pegylated antibody fragment technology to target TNF-alpha |
Rheumatoid arthritis |
The first Phase III trial of the drug in RA, Study 014, met its primary endpoint of ACR20 response at 24 weeks (3/31) |
Enzo Biochem Inc. (NYSE:ENZ) |
Alequel |
A complex of autologous colon-derived antigens administered orally |
Crohn's disease |
Interim Phase II results in 19 patients were encouraging and pointed to increasing the trial numbers (3/11) |
Genentech Inc. (NYSE:DNA) and XOMA Ltd. (XOMA) |
Raptiva (FDA- approved) |
Efalizumab; humanized antibody designed to block T cells implicated in psoriasis |
Psoriatic arthritis |
Preliminary results in a Phase II trial in 107 patients failed to demonstrate statistically significant responses at 12 weeks (3/20) |
La Jolla Pharmaceutical Co. (LJPC) |
Riquent (abetimus sodium) |
B-cell toleragen; designed to reduce levels of antibodies to double-stranded DNA |
Lupus |
One-year data from Phase III and Phase II/III trials showed a reduction of protein in urine in the drug group (3/11) |
Protein Design Labs Inc. (PDLI) |
Nuvion (visilizumab) |
Humanized antibody directed at CD3 antigen on activated T cells |
Ulcerative colitis |
Data presented from Phase I trial in 32 patients with severe disease demonstrated positive clinical responses (3/22) |
Protein Design Labs Inc. (PDLI) |
HuZAF (fontolizumab) |
Humanized anti-gamma interferon antibody |
Crohn's disease |
Drug demonstrated activity in Phase II trial with 133 patients but did not achieve statistical significance vs. placebo at day 28 (3/22) |
Serono SA (Switzerland; NYSE:SRA) |
-- |
Oral formulation of cladribine, a purine nucleoside analogue |
Multiple sclerosis |
Serono and IVAX Corp. said pharmacokinetic trials showed the drug met the targets for an orally delivered product (3/23) |
Targeted Genetics Corp. (TGEN) |
tgAAC94 |
Product using an adeno- associated viral vector to deliver a soluble TNF- alpha receptor protein |
Rheumatoid arthritis |
Company began a Phase I trial in RA patients to test safety, as well as to monitor for symptoms of disease (3/17) |
CANCER | ||||
Antisoma plc (UK; LSE:ASM) |
AS1404 |
Vascular-targeting agent designed to disrupt tumor blood vessels |
Cancers |
The third and final Phase I study provided the data needed to plan Phase II combination trials (3/22) |
Antisoma plc (UK; LSE:ASM) |
AS1405 (formerly AngioMab) |
Radiolabeled antibody that binds to a protein found around new tumor blood vessels |
Malignant brain cancer |
Company started a Phase I trial in patients to get information on safety, dosing and distribution, as well as preliminary activity (3/22) |
Array BioPharma Inc. (ARRY) |
ARRY-142886 (AZD6244) |
Small-molecule drug designed to interfere with MEK, a step in the cellular hyperproliferation pathway |
Cancers |
Array plans to begin Phase I trials evaluating tolerability and pharmacokinetics in patients with advanced disease (3/5) |
BioCryst Pharmaceuticals Inc. (BCRX) |
BCX-1777 |
Purine nucleoside phosphorylase inhibitor; blocks T-cell synthesis |
T-cell cancers |
Company began Phase IIa trial to evaluate response rate and duration in 20 patients with refractory T-cell leukemia (3/31) |
Biomira Inc. (Canada; BIOM) |
Theratope |
Vaccine combining mimic of cancer antigen sialyl-Tn and carrier molecule KLH |
Colorectal cancer |
Update from 20 patients in Phase II trial with chemotherapy showed a positive trend and no safety concerns (3/12) |
CancerVax Corp. (CNVX) |
Canvaxin |
Therapeutic whole-cell vaccine that expresses more than 20 antigens |
Stage II melanoma |
Retrospective analysis of Phase II trial showed a survival advantage for vaccine compared to historical controls (3/31) |
CancerVax Corp. (CNVX) |
Canvaxin |
Therapeutic whole-cell vaccine that expresses more than 20 antigens |
Stage III melanoma |
Monitoring board recommended Phase III trial of the immunotherapy continue, after second interim analysis; board also said Phase III Stage IV melanoma trial should continue (3/1) |
Can-Fite BioPharma Ltd.* (Israel) |
CF101 |
Oral version of agent that acts like a muscle-released molecule |
Colorectal cancer |
Interim data from Phase II trial in 56 patients showed disease stabilization in 20 of them who continued after eight weeks (3/30) |
Cell Therapeutics Inc. (CTIC) |
Pixantrone |
Anthracycline agent |
Non-Hodgkin's lymphoma |
CTI is initiating a pivotal study in about 320 patients with relapsed, aggressive disease (3/4) |
Chiron Corp. (CHIR) |
Tezacitabine |
Next-generation nucleoside analogue |
Gastroesophageal cancer |
Phase II trial did not demonstrate sufficient antitumor activity to warrant further development (3/19) |
Dendreon |
APC8024 |
Immunotherapy; vaccine that targets tumors expressing the HER-2/neu marker |
HER-2/neu- positive cancers |
Updated Phase I data showed continued clinical benefit and statistically significant T-cell immune responses in advanced breast cancer (3/29) |
EntreMed Inc. (ENMD) |
Panzem |
2-methoxyestradiol; naturally occurring metabolite of endogenous estrogen |
Cancers |
Company started a Phase I trial to test the safety and pharmacokinetics of a new formulation of the drug (3/11) |
Hybridon Inc. (AMEX:HBY) |
IMOxine (HYB2055) |
Immunomodulatory oligonucleotide; TLR9 agonist |
Cancers |
Phase I trial in healthy volunteers showed the drug was safe and biologically active (3/31) |
Introgen Therapeutics Inc. (INGN) |
Advexin |
Adenoviral vector containing the p53 tumor- suppressor gene |
Squamous-cell carcinoma of the head and neck |
Phase II trials in 217 patients with recurrent disease showed an objective overall response rate of 10% with monotherapy; stable disease or better was achieved in 59% of all treated lesions (3/30) |
Kosan Biosciences Inc. (KOSN) |
KOS-862 |
Epothilone D |
Advanced solid tumors |
Kosan began a Phase Ib trial to evaluate KOS-862 in combination with gemcitabine (3/4) |
Marshall Edwards Inc. (MSHL) |
Phenoxodiol |
Designed to induce apoptosis by removing intracellular proteins (XIAP, c-FLIP) |
Ovarian cancer |
Phase II trial in 40 late-stage, unresponsive patients produced 10 responses (3/31) |
NeoPharm Inc. (NEOL) |
IL13- E38QQR |
Tumor-targeting agent designed to deliver bacterial cytotoxic PE38 |
Glioblastoma multiforme |
Company began enrollment in Phase III Precide trial comparing drug to Gliadel wafer in about 300 patients (3/8) |
NeoRx Corp. (NERX) |
Skeletal Targeted Radiotherapy |
Bone-targeting molecule DOTMP with radioactive substance holmium-166 |
Multiple myeloma |
NeoRx began a Phase III trial in the U.S. and Canada to test the drug in 240 patients with refractory disease; the primary endpoint is complete response (3/29) |
OSI Pharmaceuticals Inc. (OSIP) and Genentech Inc. (NYSE:DNA) |
Tarceva (erlotinib) |
Small-molecule HER-1/EGFR inhibitor |
Non-small-cell lung cancer |
OSI began a Phase II trial comparing Tarceva monotherapy to standard chemotherapy in up to 102 poor-performance patients not previously treated (3/19) |
Peplin Biotech Ltd. (Australia; ASX:PEP) |
PEP005 |
Topical formulation |
Actinic keratosis and non-melanoma skin cancers |
Peplin partner Allergan Inc. filed INDs for studies of the product in AK and in basal- ell carcinoma and squamous-cell carcinoma (3/23) |
Pharmacyclics Inc. (PCYC) |
Xcytrin (motexafin gadolinium) |
Small-molecule, tumor- targeted agent from the texaphyrin class |
Chronic lymphostatic leukemia |
Company presented preliminary Phase II data showing antitumor activity in relapsed CLL, and said it was expanding trials in lymphomas (3/11) |
Pharmacyclics Inc. (PCYC) |
Xcytrin (motexafin gadolinium) |
Small-molecule, tumor- targeted agent from the texaphyrin class |
Head and neck cancer |
Interim data from Phase I trial in combination with chemoradiation showed nine of 10 patients had a complete tumor response (3/1) |
Pharmexa A/S (Denmark; CSE: PHARMX) |
HER-2 Protein AutoVac |
Therapeutic DNA vaccine designed to induce antibody responses against the HER-2 protein |
Breast cancer |
Phase I trial showed the vaccine was safe and that HER-2-specific antibody responses were seen in six of 10 patients in the trial (3/17) |
Point Therapeutics Inc. (OTC BB:POTB) |
PT-100 |
Small molecule designed to stimulate the proliferation of hematopoietic progenitor cells |
Non-small-cell lung cancer |
Company began a Phase II trial in combination with Taxotere in up to 41 patients with Stage IIIb/IV disease (3/9) |
Seattle Genetics Inc. (SGEN) |
SGN-40 |
Humanized monoclonal antibody that targets the CD40 antigen |
Multiple myeloma |
Company began a Phase I trial to evaluate safety, pharmacokinetics and antitumor activity of a multidose regimen (3/25) |
SuperGen Inc. (SUPG) |
Dacogen |
Decitabine for injection |
Myelodysplastic syndrome |
Analysis of first 45 events in a Phase III trial showed Dacogen patients had an increased time to acute myelogenous leukemia or death (3/10); final data showed different results depending on which of two measures of statistical significance was used (3/31) |
SuperGen Inc. (SUPG) |
Dacogen |
Decitabine for injection |
Hematological malignancies |
Published data from Phase I trial studying low-dose outpatient treatment showed encouraging activity (3/2) |
Telik Inc. (TELK) |
Telcyta |
Small-molecule tumor-activated drug designed to induce apoptosis |
Non-small-cell lung cancer |
Telik began Phase III ASSIST-2 trial in 520 patients to assess the reduction in the risk of death vs. Iressa (3/30) |
Telik Inc. (TELK) |
Telcyta |
Small-molecule tumor- activated drug designed to induce apoptosis |
Non-small-cell lung cancer |
Telik initiated a Phase I/IIa trial in combination with cisplatin in the front-line treatment of Stage IIIb or IV disease (3/9) |
Threshold Pharmaceuticals Inc.* |
2-deoxy- D-glucose |
Compound designed to target cells in hypoxic regions in solid tumors |
Solid tumors |
Company began a Phase I trial to test safety and pharmacokinetics and establish dosing (3/8) |
Vion Pharmaceuticals Inc. (VION) |
Cloretazine (VNP40101M) |
Sulfonyl hydrazine alkylating agent |
Acute myeloid leukemia or myelodysplastic syndromes |
Company began a Phase II trial in up to 80 patients in the U.S. and Europe to assess responses from single-agent treatment (3/29) |
CARDIOVASCULAR | ||||
Adenosine Therapeutics LLC* and Bristol-Myers Squibb Co. |
BMS068645 |
Selective A2a adenosine receptor agonist |
Cardiac perfusion imaging |
Companies started a Phase II trial testing the product as a pharmacologic stress agent in cardiac perfusion imaging studies (3/24) |
Alexion Pharmaceuticals Inc. (ALXN) and Procter & Gamble Co. |
Pexelizumab |
Monoclonal antibody; terminal complement inhibitor |
Acute cardiovascular disease |
Meta-analysis presentation of results from various trials showed significantly reduced 30-day mortality (3/8) |
Alteon Inc. (AMEX:ALT) |
ALT-711 |
Alagebrium chloride; A.G.E. crosslink breaker |
Systolic hypertension |
Company started Phase IIb trial named SPECTRA to evaluate drug's ability to lower systolic blood pressure (3/10) |
Cardiome Pharma Corp. (Canada; TSE:COM) |
RSD1235 |
Atrial anti-arrhythmic drug candidate |
Atrial fibrillation |
Company started Act 2 study that will include 210 patients; it is the second of three planned Phase III trials of the drug (3/30) |
GenVec Inc. (GNVC) |
-- |
Myoblast cell transplantation |
Congestive heart failure |
Data presented from Phase I trial showed no adverse events and the survival of human myoblasts (3/9) |
Guilford Pharmaceuticals Inc. (GLFD) |
Aggrastat (FDA-approved) |
Glycoprotein IIb/IIIa receptor antagonist |
Acute coronary syndrome |
Published data showed use of Aggrastat, along with aspirin, heparin and coronary stenting, with early intervention provided statistically significant benefit compared to early intervention alone (3/2) |
Human Genome Sciences Inc. (HGSI) |
677116 |
Small-molecule inhibitor of lipoprotein-associated phospholipase A2 |
Cardiovascular disease |
Partner GlaxoSmithKline plc initiated a Phase I trial of the drug (3/30) |
Myogen Inc. (MYOG) |
Enoximone |
Small-molecule inhibitor of Type-III phospho- diesterase |
Chronic heart failure |
Phase III EMOTE study failed to reach statistical significance in weaning patients off inotrope therapy; secondary endpoints were reached (3/25) |
NitroMed Inc. (NTMD) |
BiDil |
Nitric oxide-enhancing oral agent |
Heart failure |
Monitoring board conducted third interim analysis and found no safety concerns, recommending Phase III trial in African-Americans continue (3/16) |
CENTRAL NERVOUS SYSTEM | ||||
Neurocrine Biosciences Inc. (NBIX) |
Indiplon |
Modified-release form of agent that acts on the GABA-A receptor |
Insomnia |
Long-term data from Phase III SLEEP and RESTFUL trials demonstrated statistical significance in primary and secondary endpoints; an NDA is being planned (3/24) |
Neurocrine Biosciences Inc. (NBIX) |
Indiplon |
Modified-release form of agent that acts on the GABA-A receptor |
Insomnia |
Phase III trial in elderly patients with chronic insomnia achieved statistically significant total sleep time vs. placebo (3/2) |
Neurocrine Biosciences Inc. (NBIX) |
Indiplon |
Modified-release form of agent that acts on the GABA-A receptor |
Insomnia |
Phase III trial in 325 healthy adults with transient insomnia demonstrated statistically significant benefit vs. placebo (3/1) |
NeuroMed Technologies Inc.* (Canada) |
NMED-160 |
Calcium-channel blocker |
Chronic pain |
Company began a Phase I trial to evaluate the safety, tolerability and pharmacokinetics in healthy individuals (3/11) |
Pain Therapeutics Inc. (PTIE) |
Oxytrex |
Oral agent designed to inhibit an excitatory effect of opioid receptors |
Pain |
Company began a second Phase III trial; it will be compared to placebo and oxycodone in 700 patients with moderate to severe osteoarthritic pain (3/30) |
DIABETES | ||||
Amylin Pharmaceuticals Inc. (AMLN) |
Exenatide LAR |
Long-acting formulation of synthetic exendin-4 |
Type II diabetes |
Company began a Phase II trial to assess dosing in up to 60 patients; the product is being developed with Alkermes Inc. and Eli Lilly and Co. (3/30) |
Generex Biotechnology Corp. (GNBT) |
Oralin |
Oral insulin spray formulation |
Type II diabetes |
Published data on trial with 21 patients showed agent could be used as an add-on therapy (3/8) |
Ligand Pharmaceuticals Inc. (LGND) and Eli Lilly and Co. |
LY519818 |
Oral, once-daily peroxi- some proliferator- activated receptor modulator |
Type II diabetes |
Lilly decided to move product into registrational Phase III trials (3/2) |
Metabolex Inc.* |
MBX-102 |
Insulin sensitizer |
Type II diabetes |
Company began a Phase II study in about 200 patients in the U.S. and Mexico, who are using insulin but who have poor fasting blood-glucose levels (3/2) |
INFECTION | ||||
Adventrx Pharmaceuticals Inc.* |
BlockAide/CR |
Peptide-based drug designed to block viral entry |
HIV |
Company filed IND to begin its clinical program for the product (3/4) |
Basilea Pharmaceutica AG (Switzerland; SWX:BSLN) |
BAL5788 |
Broad-spectrum cephalosporin antibiotic |
Skin and skin- structure infections |
Phase II trial showed no failures among 35 evaluable patients (3/3) |
CytRx Corp. (CYTR) and Advanced BioScience Laboratories* |
-- |
Polyvalent HIV vaccine based on five strains of HIV |
HIV |
The University of Massachusetts Medical School is starting a Phase I trial in 36 patients; the vaccine was created by UMMS and ABL (3/23) |
Depomed Inc. (DEPO) |
Ciprofloxacin GR |
Extended-release form- ulation of ciprofloxacin |
Urinary tract infections |
Phase III data showed product eliminated the organisms responsible for infections as effectively as twice-daily Cipro with fewer gastrointestinal side effects (3/18) |
Hemispherx Biopharma Inc. (AMEX:HEB) |
Alferon LDO |
Low-dose, oral natural alpha interferon |
HIV |
Company began a Phase II trial in asymtomatic patients to evaluate safety and activity (3/2) |
Human Genome Sciences Inc. (HGSI) |
ABthrax |
Human monoclonal anti- body to Bacillus anthracis protective antigen |
Anthrax infection |
Phase I data showed the product was safe and well tolerated in healthy volunteers, and that desired blood levels were achieved (3/9) |
Immtech International Inc. (AMEX:IMM) |
DB289 |
Oral antiviral agent |
African sleeping sickness |
Immtech filed an IND for a trial testing oral administration of the drug in Stage I disease (3/23) |
Inhibitex Inc.* |
Aurexis |
Human monoclonal antibody |
Staphylococcus aureus infections |
Company began enrollment in a Phase II trial testing drug in first- line treatment with standard-of-care antibiotics |
Medinox Inc.* |
Norathiol (NOX-100) |
Nitric oxide neutralizer |
Septic shock |
Data presented from Phase I/II trial indicated a beneficial effect and a good safety profile (3/8) |
Panacos Pharmaceuticals Inc.* |
PA-457 |
Small-molecule drug from new class named maturation inhibitors |
HIV |
Panacos began a Phase I trial in healthy volunteers to assess safety and pharmacokinetics (3/16) |
Peninsula Pharmaceuticals Inc.* |
Doripenem (S-4661) |
Agent from the carbapenem class of beta-lactam antibiotics |
Complicated intra- abdominal infections |
Company began two Phase III trials to evaluate intravenous form of drug (3/30) |
PharmAthene, Inc.* |
ToxBlox |
Mutated anthrax protective antigen designed to prevent release of anthrax toxins into the cell |
Anthrax infection |
Company submitted an IND for a Phase I trial to test the product in healthy volunteers (3/31) |
Serono SA (Switzerland; NYSE:SRA) |
Serostim (FDA- approved) |
Somatropin for injection |
AIDS wasting |
Published results showed drug approved superior to placebo in international trial with 757 patients (3/31) |
VaxGen Inc. (VXGN) |
rPA102 |
Recombinant protective antigen anthrax vaccine |
Anthrax infection |
Phase I trial demonstrated comparable immune responses to Anthrax Vaccine Adsorbed, a licensed anthrax vaccine (3/2) |
Vical Inc. (VICL) |
-- |
Gene-based immunotherapeutic vaccine encoding two immunogens |
Cytomegalovirus |
Vical began a Phase I trial to test safety and immune responses in healthy volunteers (3/31) |
Vicuron Pharmaceuticals Inc. (MICU) |
Anidulafungin |
Broad-spectrum agent from the echinocandin class |
Invasive aspergillosis |
Phase III results showed product could be combined with liposomal amphotericin B without increased side effects (3/24) |
MISCELLANEOUS | ||||
Alkermes Inc. (ALKS) |
AIR Epinephrine |
Inhaled formulation of epinephrine |
Anaphylaxis |
The product demonstrated rapid systemic delivery in a Phase I trial in normal volunteers, with no safety problems (3/22) |
Amylin Pharmaceuticals Inc. (AMLN) |
AC162352 (PYY 3-36) |
Y2 receptor agonist |
Obesity |
Amylin began a Phase I study to assess safety in up to 80 healthy volunteers (3/30) |
BioGentech Corp. (OTC BB: BGTH) |
Prehistin |
Sublingual lozenge designed to modulate IgE |
Seasonal allergic rhinitis |
Company began a Phase III trial to evaluate the drug in up to 1,000 allergy sufferers (3/29) |
Discovery Laboratories Inc. (DSCO) |
DSC-104 |
Aerosol formualtion of humanized lung surfactant |
Asthma |
Phase Ib trial showed product was safe, well tolerated, did not induce bronchospasm, and was deposited to the lungs (3/9) |
Eyetech Pharmaceuticals Inc. (EYET) |
Macugen |
Pegaptanib sodium; vascular endothelial growth factor inhibitor |
Wet age-related macular degeneration |
Additional data presented from pivotal trials showed efficacy was independent of lesion size and patient age (3/4) |
InKine Pharmaceutical Co. Inc. (INKP) |
INKP-102 |
New-generation sodium phosphate purgative tablet |
Colon-cleansing agent |
Company began dosing in Phase II trial to compare several doses to its marketed Visicol tablets in adults scheduled for colonoscopy (3/22) |
InterMune Inc. (ITMN) |
Actimmune |
Interferon gamma-1b |
Idiopathic pulmonary fibrosis |
Phase II trial provided evidence of altered expression of biomarkers involved in IPF (3/30) |
ISTA Pharmaceuticals Inc. (ISTA) |
Xibrom |
Topical non-steroidal anti-inflammatory solution |
Ocular inflammation following cataract surgery |
Two Phase III trials demonstrated statistical significance in the pri- mary endpoint of proportion of patients with complete absence of ocular inflammation (3/9) |
Maxim Pharmaceuticals Inc. (MAXM) |
HD-O |
Oral histamine dihydro- chloride drug candidate |
Chronic liver diseases |
Company completed a Phase Ia pharmacokinetic trial to deter- mine dosing and set the stage for further trials (3/23) |
Nastech Pharmaceutical Co. Inc. (NSTK) |
-- |
Nasal formulation of apomorphine |
Sexual dysfunction |
A Phase II trial in 102 men showed the product was safe, and established dosing information (3/10) |
Nastech Pharmaceutical Co. Inc. (NSTK) |
PYY 3-36 |
Nasal spray formulation of high-affinity Y2 receptor agonist |
Obesity |
Phase Ib study in 11 overweight subjects showed a reduced aver- age calorie intake and reduced appetite (3/10) |
NexMed Inc. (NEXM) |
NM100061 |
Product combining ingredients for treating premature ejaculation with NexACT delivery technology |
Premature ejaculation |
Pilot study in 89 patients showed it met endpoints of extending the ejaculatory latency time and improving overall satisfaction (3/22) |
NPS Pharmaceuticals Inc. (NPSP) |
Preos |
Recombinant human parathyroid hormone |
Osteoporosis |
Phase III trial met the primary endpoint of reducing new or worsened vertebral fractures in postmenopausal women with mild to moderate osteoporosis; an NDA filing is planned (3/30) |
Protein Design Labs Inc. (PDLI) |
Daclizumab (FDA-approved as Zenapax) |
Humanized monoclonal antibody; interleukin-2 receptor antagonist |
Asthma |
Phase II study in patients with chronic, persistent disease demonstrated statistical significance in percent change in FEV1 from baseline to 12 weeks (3/15) |
Regeneron Pharmaceuticals Inc. (REGN) and Aventis SA (France) |
VEGF Trap |
Intravenous product designed to block vascular endothelial growth factor |
Wet age-related macular degeneration |
Companies began Phase I trial to assess safety and tolerability and preliminary effects on visual acuity (3/9) |
Rigel Pharmaceuticals Inc. (RIGL) |
R112 |
Agent designed to interrupt the signal from the IgE receptor |
Allergic rhinitis |
Data from Phase I/II trial were presented showing R112 was well tolerated and produced favorable biological effects (3/18) |
Serono SA (Switzerland; NYSE:SRA) |
Serostim |
Somatropin (rDNA origin) for injection |
HIV-associated adipose redistribution syndrome |
Published study on 239 patients showed statistically significant decrease in visceral adipose tissue; product also met secondary end- points (3/1) |
Zelos Therapeutics Inc.* |
Ostabolin-C |
Parathyroid hormone analogue |
Osteoporosis |
Zelos began a Phase Ia trial of the product (3/9) |
Notes: | ||||
* Privately held | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange. | ||||
